Home > Haematology > ASH 2021 > Multiple Myeloma > GRIFFIN: Sustained responses of daratumumab plus RVd in MM

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented by
Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA
ASH 2021
Phase 2, GRIFFIN
Patients with transplant-eligible, newly diagnosed multiple myeloma (MM) continued to benefit from daratumumab plus lenalidomide, bortezomib, and dexamethasone (RVd) after 24 months of maintenance therapy. New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1].

In the phase 2 GRIFFIN trial (NCT02874742), patients with newly diagnosed MM, eligible for high-dose therapy and autologous haematopoietic cell transplantation (HCT) were randomised 1:1 to receive daratumumab plus RVd (n=104) or RVd alone (n=103). Patients were subjected to 4 cycles of high-dose daratumumab plus RVd or RVd alone, followed by autologous HCT and 2 consolidation cycles of daratumumab plus RVd or RVd alone. Subsequently, the patients received maintenance therapy of lenalidomide plus daratumumab or lenalidomide alone for 24 months. Dr Jacob Laubach (Dana-Farber Cancer Institute, MA, USA) presented the results after completion of maintenance therapy.

The primary analysis showed that patients receiving the daratumumab combination regimen had a numerically higher stringent complete response (sCR) rate after completion of consolidation therapy than patients who received RVd alone (42.4% vs 32.0%; P=0.068). After 24 months of maintenance therapy, the rate of sCR was 66.0% and 47.4% in patients receiving daratumumab plus RVd and RVd alone, respectively (P=0.0096). In addition, patients receiving the daratumumab combination regimen displayed a higher MRD-negativity rate than patients receiving RVd alone (64.4% vs 30.1%; P<0.0001). Median progression-free survival (PFS) was not reached after 38.6 months of follow-up, with a PFS rate of 88.9% in the daratumumab plus RVd arm and a PFS rate of 81.2% in the RVd alone arm. The safety analysis did not reveal new issues.

Dr Laubach argued that these updated results indicate that daratumumab plus RVd induction therapy followed by daratumumab consolidation and maintenance therapy is a promising regimen for patients with transplant-eligible, newly diagnosed MM.

  1. Laubach JP, et al. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Abstract 79, ASH 2021 Annual Meeting, 11‚Äď14 December.


Copyright ©2022 Medicom Medical Publishers

Posted on